Levonorgestrel/Ethinyl Estradiol

Phase 1Small molecule

Pfizer

Levonorgestrel/Ethinyl Estradiol is one of 16 small molecule programs targeting Female. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

FemaleRecruiting

FemalePhase 1

Recruiting

Competition

Competitive Landscape

19 competitors in Female

#DrugCompanyPhaseTrials

Activella

Eli Lilly

Approved

2 2

Dostarlimab

Incyte

Phase 2

1 3

Jemperli

GGlaxo Dba Glaxosmithkline

Phase 2

1 4

Versed

CConrado Roberto Hoffmann Filho

Phase 1

3 5

Faslodex

FFresenius Kabi USA, LLC

Phase 1

2 6

Isentress

CCidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)

Preclinical

1 7

Alli

EEngelhard Arzneimittel GmbH & Co.KG

Preclinical

1 8

Questran

KKaruna Therapeutics, Inc., a Bristol Myers Squibb company

Preclinical

1 9

MK-8527

Merck & Co.

Phase 1

1 10

HRS-8080

SShandong Suncadia Medicine Co., Ltd.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Post-ApprovalRecruiting

Study completion

NCT05058872

Clinical

Trials by Indication[1]

Cycling2 trials

Study Evaluating the Bioequivalence of Levonorgestrel/Ethinyl Estradiol Combinations in Cycling Women

Withdrawn· Pfizer logo

Pfizer·Phase 1·NCT00447863

Study Comparing Two Manufacturing Processes for Levonorgestrel 90 mg/Ethinyl Estradiol 20 mg (LNG/EE) in Healthy, Cycling Women

Completed· Pfizer logo

Pfizer·Phase 1·NCT00319163·26 enrolled

Interaction1 trial

A Study to Evaluate the Drug Interaction Between Povorcitinib and the Oral Contraceptive Levonorgestrel/Ethinyl Estradiol in Healthy Adult Females

Completed· Incyte logo

Incyte·Phase 1·NCT06380205·24 enrolled

Female1 trial

A Study of Elenestinib in Healthy Adult Female Participants

Recruiting·BBlueprint Medicines·Phase 1·NCT07388511·20 enrolled

Unspecified5 trials

Contraceptive Hormone and Reward Measurement (CHARM Study)

Recruiting·UUniversity of Colorado, Denver·Phase 4·NCT05058872·144 enrolled

Study Evaluating Combination of Levonorgestrel (LNG) and Ethinyl Estradiol (EE) in Premenstrual Dysphoric Disorder

Completed· Pfizer logo

Pfizer·Phase 3·NCT00128934·744 enrolled

Study Evaluating Levonorgestrel/Ethinyl Estradiol (LNG/EE) in PMS

Completed· Pfizer logo

Pfizer·Phase 3·NCT00161681·200 enrolled

Show 2 more trials

Study Evaluating Combination of Levonorgestrel and Ethinyl Estradiol in Pre-Menstrual Dysphoric Disorder

Completed· Pfizer logo

Pfizer·Phase 3·NCT00195559·526 enrolled

A Phase 1 Drug-Drug Interaction Study of ABBV-295, Levonorgestrel, and Ethinyl Estradiol in Healthy Adult Female Subjects With Overweight or Obesity

Completed· AbbVie logo

AbbVie·Phase 1·NCT07414784·20 enrolled

Sources

References

[1]
ClinicalTrials.gov — 9 trial records for Levonorgestrel/Ethinyl Estradiol. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Levonorgestrel/Ethinyl Estradiol compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Levonorgestrel/Ethinyl Estradiol. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Pfizer company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 1[1]
Company: Pfizer

Levonorgestrel/Ethinyl Estradiol

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Trials by Indication[1]

Cycling2 trials

Interaction1 trial

Female1 trial

Unspecified5 trials

References

Drug Info

Quick Facts

Related News